Here are the 10-K annual reports from Co-Diagnostics, Inc. (CODX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CODX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CODX filings page.
Co-Diagnostics, Inc. (CODX) files its annual report describing a specialty PCR diagnostics business while warning of substantial doubt about its ability to continue as a going concern. The company develops lab-based and point-of-care PCR tests, including a Co-Dx PCR Pro platform still awaiting key regulatory clearances.
CODX reports cash and cash equivalents of $11.9 million and an accumulated deficit that widened to $80.4 million, reflecting ongoing losses. It is funding operations through grants and at-the-market equity programs and highlights significant dependence on a few customers and granting agencies. Extensive risk factors cover regulation, competition, supply-chain reliance, data privacy, and the need for additional capital to advance its multiplex respiratory and global infectious disease testing strategy.